Search hospitals > Illinois > Harvey
UChicago Medicine Ingalls Memorial
Claim this profileHarvey, Illinois 60426
Conducts research for Colorectal Cancer
Conducts research for Plasma Cell Neoplasms
Conducts research for Multiple Myeloma
Conducts research for Tumors
3 reported clinical trials
0 medical researchers
Summary
UChicago Medicine Ingalls Memorial is a medical facility located in Harvey, Illinois. This center is recognized for care of Colorectal Cancer, Plasma Cell Neoplasms, Multiple Myeloma, Tumors and other specialties. UChicago Medicine Ingalls Memorial is involved with conducting 3 clinical trials across 4 conditions. There are 0 research doctors associated with this hospital, such as .Area of expertise
1Colorectal Cancer
Stage IV
BRAF positive
dMMR positive
2Plasma Cell Neoplasms
Top PIs
Clinical Trials running at UChicago Medicine Ingalls Memorial
Colorectal Cancer
Tumors
Plasma Cell Neoplasms
Multiple Myeloma
Encorafenib + Cetuximab
for Colorectal Cancer
The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the potential treatment of colorectal cancer that: has spread to other parts of the body (metastatic); has a certain type of abnormal gene called "BRAF"; and has not received prior treatment. Participants in this study will receive one of the following study treatments: Encorafenib plus cetuximab: These participants will receive encorafenib by mouth at home every day and cetuximab once every two weeks by intravenous (IV) infusion (an injection into the vein) at the study clinic. Encorafenib plus cetuximab with chemotherapy: These participants will receive encorafenib and cetuximab in the way described in the bullet above. Additionally, they will receive standard chemotherapy by IV infusion and oral treatment at home. Chemotherapy alone: These participants will receive chemotherapy, the standard treatment for this condition, by IV infusion at the study clinics and oral treatment at home. The study team will monitor how each participant responds to the study treatment for up to about 3 years.
Recruiting2 awards Phase 310 criteria
Encorafenib + Cetuximab and Pembrolizumab
for Colorectal Cancer
The purpose of this study is to learn about the effects of three study medicines (encorafenib, cetuximab, and pembrolizumab) given together for the treatment of colorectal cancer that: is metastatic (spread to other parts of the body); has the condition of genetic hypermutability (tendency to mutation) or impaired DNA mismatch repair (MMR) has a certain type of abnormal gene called "BRAF" and; has not received prior treatment. All participants in this study will receive pembrolizumab at the study clinic as an intravenous (IV) infusion (given directly into a vein) at the study clinic. In addition, half of the participants will take encorafenib by mouth at home every day and cetuximab by IV infusion at the study clinic. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.
Recruiting1 award Phase 2
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at UChicago Medicine Ingalls Memorial?
UChicago Medicine Ingalls Memorial is a medical facility located in Harvey, Illinois. This center is recognized for care of Colorectal Cancer, Plasma Cell Neoplasms, Multiple Myeloma, Tumors and other specialties. UChicago Medicine Ingalls Memorial is involved with conducting 3 clinical trials across 4 conditions. There are 0 research doctors associated with this hospital, such as .